Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2

Journal of Medicinal Chemistry

Volumn 54, Issue 13, 2011, Pages 4548-4558

  Kido, Yasuto ^a,b   Matsson, Pär ^a,c   Giacomini, Kathleen M ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHIONOGI AND CO LTD   (Japan)

^c UPPSALA UNIVERSITY   (Sweden)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; BENZATROPINE; BENZETHONIUM CHLORIDE; BITHIONOL; BUFLOMEDIL; CHLORHEXIDINE; CHLORPHENESIN CARBAMATE; CRYSTAL VIOLET; DICYCLOVERINE; EPINASTINE; EXEMESTANE; GABEXATE; GUANABENZ; IMATINIB; IPRATROPIUM BROMIDE; MEBEVERINE; OLANZAPINE; ORGANIC CATION TRANSPORTER 2; PENTAMIDINE; PERFLUORODECALIN; PHENYLTOLOXAMINE; PIPETHANATE; PROCYCLIDINE; PROPANTHELINE BROMIDE; RABEPRAZOLE; SPARTEINE; SULCONAZOLE; TACRINE; TETRACHLORSALAN; TOLTERODINE;

ARTICLE; DRUG INTERACTION; DRUG SCREENING; HUMAN; HUMAN CELL; KIDNEY;

DRUG INTERACTIONS; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; KIDNEY; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; ORGANIC CATION TRANSPORT PROTEINS; POLYMORPHISM, GENETIC; PRESCRIPTION DRUGS; PROTEIN BINDING; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79960155485     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2001629     Document Type: Article

References (46)

1. Varma, M. V.; Feng, B.; Obach, R. S.; Troutman, M. D.; Chupka, J.; Miller, H. R.; El-Kattan, A. Physicochemical determinants of human renal clearance J. Med. Chem. 2009, 52, 4844-4852
2. Cundy, K. C. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir Clin. Pharmacokinet. 1999, 36, 127-143 (Pubitemid 29121686)
3. Jaehde, U.; Sorgel, F.; Reiter, A.; Sigl, G.; Naber, K. G.; Schunack, W. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans Clin. Pharmacol. Ther. 1995, 58, 532-541
4. Hedaya, M. A.; Elmquist, W. F.; Sawchuk, R. J. Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers Pharm. Res. 1990, 7, 411-417 (Pubitemid 20266600)
5. Somogyi, A.; Stockley, C.; Keal, J.; Rolan, P.; Bochner, F. Reduction of metformin renal tubular secretion by cimetidine in man Br. J. Clin. Pharmacol. 1987, 23, 545-551 (Pubitemid 17087957)
6. Fletcher, C. V.; Henry, W. K.; Noormohamed, S. E.; Rhame, F. S.; Balfour, H. H., Jr. The effect of cimetidine and ranitidine administration with zidovudine Pharmacotherapy 1995, 15, 701-708
7. Brunton, L.; Lazo, J.; Parker, K., Eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11 th ed.; McGraw-Hill, Inc.: New York, NY, 2005.
8. Gorboulev, V.; Ulzheimer, J. C.; Akhoundova, A.; UlzheimerTeuber, I.; Karbach, U.; Quester, S.; Baumann, C.; Lang, F.; Busch, A. E.; Koepsell, H. Cloning and characterization of two human polyspecific organic cation transporters DNA Cell Biol. 1997, 16, 871-881 (Pubitemid 27332696)
9. Motohashi, H.; Sakurai, Y.; Saito, H.; Masuda, S.; Urakami, Y.; Goto, M.; Fukatsu, A.; Ogawa, O.; Inui, K. Gene expression levels and immunolocalization of organic ion transporters in the human kidney J. Am. Soc. Nephrol. 2002, 13, 866-874 (Pubitemid 34274082)
10. Chen, Y.; Li, S.; Brown, C.; Cheatham, S.; Castro, R. A.; Leabman, M. K.; Urban, T. J.; Chen, L.; Yee, S. W.; Choi, J. H.; Huang, Y.; Brett, C. M.; Burchard, E. G.; Giacomini, K. M. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin Pharmacogenet. Genomics 2009, 19, 497-504
11. Shu, Y.; Brown, C.; Castro, R. A.; Shi, R. J.; Lin, E. T.; Owen, R. P.; Sheardown, S. A.; Yue, L.; Burchard, E. G.; Brett, C. M.; Giacomini, K. M. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics Clin. Pharmacol. Ther. 2008, 83, 273-280
12. Zhang, S. Z.; Lovejoy, K. S.; Shima, J. E.; Lagpacan, L. L.; Shu, Y.; Lapuk, A.; Chen, Y.; Komori, T.; Gray, J. W.; Chen, X.; Lippard, S. J.; Giacomini, K. M. Organic cation transporters are determinants of oxaliplatin cytotoxicity Cancer Res. 2006, 66, 8847-8857 (Pubitemid 44449203)
13. Jung, N.; Lehmann, C.; Rubbert, A.; Knispel, M.; Hartmann, P.; van Lunzen, J.; Stellbrink, H. J.; Faetkenheuer, G.; Taubert, D. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection Drug Metab. Dispos. 2008, 36, 1616-1623
14. Neuvonen, P. J.; Niemi, M.; Backman, J. T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance Clin. Pharmacol. Ther. 2006, 80, 565-581 (Pubitemid 44908269)
15. Highlights of Prescribing Information: Tracleer (Bosentan); Actelion Pharmaceuticals US, Inc.: South San Francisco, CA, 2009; Approved by U.S. Food and Drug Administration and available on the U.S. FDA Web site as http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/021290s012lbl.pdf.
16. Guidance for Industry. Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling; U.S. Food and Drug Administration, 2006; http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf.
17. Guideline on the Investigation of Drug Interactions; European Medicines Agency: London, U.K., 2010; http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2010/05/WC500090112.pdf.
18. Lazarou, J.; Pomeranz, B. H.; Corey, P. N. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies JAMA, J. Am. Med. Assoc. 1998, 279, 1200-1205 (Pubitemid 28193431)
19. Pirmohamed, M.; James, S.; Meakin, S.; Green, C.; Scott, A. K.; Walley, T. J.; Farrar, K.; Park, B. K.; Breckenridge, A. M. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients Br. Med. J. 2004, 329, 15-19 (Pubitemid 38869995)
20. Wienkers, L. C.; Heath, T. G. Predicting in vivo drug interactions from in vitro drug discovery data Nat. Rev. Drug Discovery 2005, 4, 825-833 (Pubitemid 41553963)
21. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek-Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development Nat. Rev. Drug Discovery 2010, 9, 215-236
22. Abel, S.; Nichols, D. J.; Brearley, C. J.; Eve, M. D. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide Br. J. Clin. Pharmacol. 2000, 49, 64-71 (Pubitemid 30050488)
23. Feng, B.; Obach, R. S.; Burstein, A. H.; Clark, D. J.; de Morais, S. M.; Faessel, H. M. Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study Clin. Pharmacol. Ther. 2008, 83, 567-576 (Pubitemid 351417059)
24. Shiga, T.; Hashiguchi, M.; Urae, A.; Kasanuki, H.; Rikihisa, T. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans Clin. Pharmacol. Ther. 2000, 67, 222-228 (Pubitemid 30176379)
25. Somogyi, A. A.; Bochner, F.; Sallustio, B. C. Stereoselective inhibition of pindolol renal clearance by cimetidine in humans Clin. Pharmacol. Ther. 1992, 51, 379-387
26. Ahlin, G.; Karlsson, J.; Pedersen, J. M.; Gustavsson, L.; Larsson, R.; Matsson, P.; Norinder, U.; Bergstrom, C. A.; Artursson, P. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1 J. Med. Chem. 2008, 51, 5932-5942
27. Gorboulev, V.; Shatskaya, N.; Volk, C.; Koepsell, H. Subtype-specific affinity for corticosterone of rat organic cation transporters rOCT1 and rOCT2 depends on three amino acids within the substrate binding region Mol. Pharmacol. 2005, 67, 1612-1619 (Pubitemid 40594160)
28. Singh, S. K.; Piscitelli, C. L.; Yamashita, A.; Gouaux, E. A competitive inhibitor traps LeuT in an open-to-out conformation Science 2008, 322, 1655-1661
29. Zhou, Z.; Zhen, J.; Karpowich, N. K.; Law, C. J.; Reith, M. E. A.; Wang, D. N. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures Nat. Struct. Mol. Biol. 2009, 16, 652-657
30. Feng, B.; LaPerle, J. L.; Chang, G.; Varma, M. V. Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state Expert Opin. Drug Metab. Toxicol. 2010, 6, 939-952
31. Zhang, X. H.; Shirahatti, N. V.; Mahadevan, D.; Wright, S. H. A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2) J. Biol. Chem. 2005, 280, 34813-34822 (Pubitemid 41504615)
32. Matsushima, S.; Maeda, K.; Inoue, K.; Ohta, K. Y.; Yuasa, H.; Kondo, T.; Nakayama, H.; Horita, S.; Kusuhara, H.; Sugiyama, Y. The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine Drug Metab. Dispos. 2009, 37, 555-559
33. Tsuda, M.; Terada, T.; Ueba, M.; Sato, T.; Masuda, S.; Katsura, T.; Inui, K. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells J. Pharmacol. Exp. Ther. 2009, 329, 185-191
34. Chen, Y.; Zhang, S.; Sorani, M.; Giacomini, K. M. Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family J. Pharmacol. Exp. Ther. 2007, 322, 695-700 (Pubitemid 47105798)
35. Lee, W. K.; Reichold, M.; Edemir, B.; Ciarimboli, G.; Warth, R.; Koepsell, H.; Thevenod, F. Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule Am. J. Physiol.: Renal Physiol. 2009, 296, F1504-F1513
36. Filipski, K. K.; Mathijssen, R. H.; Mikkelsen, T. S.; Schinkel, A. H.; Sparreboom, A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity Clin. Pharmacol. Ther. 2009, 86, 396-402
37. Vistide (Cidofovir Injection); Gilead Sciences, 2000; Available from U.S. Food and Drug Administration at http://www.accessdata.fda.gov/drugsatfda-docs/ label/1999/020638s003lbl.pdf.
38. Lalezari, J. P.; Kuppermann, B. D. Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 1997, 14, S27-S31
39. Zhang, J. H.; Chung, T. D.; Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screening 1999, 4, 67-73 (Pubitemid 29278954)
40. DiGregorio, G. J.; Barbieri, E. J., Eds. Handbook of Commonly Prescribed Drugs with Therapeutic, Toxic and Lethal Levels, 19 th ed.; Medical Surveillance, Inc.: West Chester, PA, 2005.
41. Moffat, A. C.; Osselton, M. D.; Widdop, B.; Galichet, L. Y., Eds. Clarke's Analysis of Drugs and Poisons, 3 rd ed.; Pharmaceutical Press: London, U.K., 2004.
42. Berthold, M. R.; Hofer, H.; Borgelt, C. Mining molecular fragments with MoFa. Finding relevant substructures in sets of molecules Abstr. Pap.-Am. Chem Soc. 2003, 225, U554-U554
43. Matsson, P.; Bergstrom, C. A.; Nagahara, N.; Tavelin, S.; Norinder, U.; Artursson, P. Exploring the role of different drug transport routes in permeability screening J. Med. Chem. 2005, 48, 604-613 (Pubitemid 40139802)
44. Freyhult, E.; Prusis, P.; Lapinsh, M.; Wikberg, J. E.; Moulton, V.; Gustafsson, M. G. Unbiased descriptor and parameter selection confirms the potential of proteochemometric modelling BMC Bioinf. 2005, 6, 50
45. Barberi, M.; Merlin, J. L.; Weber, B. Sensitive determination of free and plasma protein-bound dipyridamole by high-performance liquid chromatography J. Chromatogr. 1991, 565, 511-515
46. MacGregor, T. R.; Sardi, E. D. In vitro protein binding behavior of dipyridamole J. Pharm. Sci. 1991, 80, 119-120